Dale Shepard
Hematology & Oncology · Cleveland, OHNPI 1790955623
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $207,078 of the $313,919 with a category attached, or 66.0%. 20 manufacturers reported payments, led by Sanofi at 55.8% of the total. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $1121.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$175K
- Springworks Therapeutics, Inc.$39K
- Deciphera Pharmaceuticals Inc.$35K
- Bristol Myers Squibb$14K
- Pfizer$12K
- Aadi Bioscience, Inc.$10K
- plus $29K from 14 others
Across 308 payments — averaging $15,548 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$2.4M
- Aadi Bioscience, Inc.$584K
- Pfizer$556K
- Astellas Pharma Global Development$275K
- Seagen Inc.$208K
- Eli Lilly$191K
- plus $548K from 11 others
What the payments were for
- Consulting fees$207,07866%
- Speaking & faculty fees$74,13924%
- Travel & lodging$25,6048%
- Food & beverage$7,0022%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 99 | $175,122 |
| Springworks Therapeutics, Inc. | 31 | $39,309 |
| Deciphera Pharmaceuticals Inc. | 47 | $34,522 |
| Bristol Myers Squibb | 20 | $14,175 |
| Pfizer | 6 | $11,861 |
| Aadi Bioscience, Inc. | 13 | $10,333 |
| Lilly USA, LLC | 4 | $7,425 |
| Ipsen Biopharmaceuticals, Inc | 7 | $7,306 |
| Genentech USA, Inc. | 6 | $5,542 |
| Daiichi Sankyo Inc. | 3 | $3,210 |
| Bayer | 2 | $2,398 |
| Taiho Oncology, Inc. | 1 | $1,313 |
| Amgen | 26 | $530 |
| Novartis | 4 | $281 |
| Seagen Inc. | 2 | $230 |
| Merck | 3 | $102 |
| Boehringer Ingelheim | 3 | $96 |
| Astellas Pharma US Inc | 1 | $95 |
| Mindray DS USA, Inc. | 1 | $45 |
| Incyte Corporation | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$313,919 in reported general payments places this provider in the 95th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QinlockRipretinib | 17 | $702,126 |
| OgsiveoNirogacestat Hydrobromide | 17 | $489,076 |
| IbrancePalbociclib | 30 | $460,981 |
| Pazopanib Hcl | 25 | $156,846 |
| Imatinib Mesylate | 40 | $57,407 |
| Ondansetron Hcl | 12 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Deciphera Pharmaceuticals Inc.Qinlock | $34,522 | $702,12617 claims |
| Springworks Therapeutics, Inc.Ogsiveo | $39,309 | $489,07617 claims |
| PfizerIbrance | $11,861 | $460,98130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
- Afshin DowlatiCleveland$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.